Propanc Biopharma (PPCB) Short Interest Ratio & Short Volume

Short interest is the volume of Propanc Biopharma shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 100 shares of PPCB short. 0.00% of Propanc Biopharma's shares are currently sold short. Learn More on Propanc Biopharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Propanc Biopharma's floating shares are currently sold short.

Propanc Biopharma saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 100 shares, an increase of ∞ from the previous total of 0 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Propanc Biopharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Propanc Biopharma: Virpax Pharmaceuticals, Inc. (0.30%), Kiromic BioPharma, Inc. (0.01%), Capstone Holding Corp. (0.11%), NuCana plc (48.60%), Bon Natural Life Ltd (101.02%), TC Biopharm (Holdings) Plc (176.43%), Vincerx Pharma, Inc. (0.05%), Ampio Pharmaceuticals, Inc. (0.01%), GlobeStar Therapeutics Co. (0.00%), Navidea Biopharmaceuticals, Inc. (0.00%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks.

Short selling PPCB is an investing strategy that aims to generate trading profit from Propanc Biopharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Propanc Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PPCB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PPCB, twice per month. The most recent reporting period available is May, 15 2025.